Surveillance of Circulating Tumor Cell Phenotype in Early Stage Breast Cancer Patients With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Neoplasms
- Sponsor
- Hunan Cancer Hospital
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- iDFS
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
The phenotype of circulating tumor cells (CTCs) is supposed to be significant indicator that is correlated the prognosis of breast cancer patients who have completed neoadjuvant chemotherapy, primary tumor surgery with/without adjuvant chemotherapy. The aim of this observational study is to assess the efficacy of CTCs surveillance in predicting the prognosis of breast cancer patients.
Detailed Description
The aim of this observational study is to assess the efficacy of CTCs surveillance in predicting the treatment response of neoadjuvant chemotherapy, surgery and adjuvant chemotherapy. This study also aims to evaluate the efficacy of CTCs surveillance in predicting invasive-disease free survival (iDFS), overall survival (OS) and metastasis. Additionally, this study evaluate the expression of PDL1 and FOXC3 on CTCs.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
iDFS
Time Frame: From date of enrollment through study completion, up to 10 years.
The survival time from the date of tumor resection to the date of the relapse of the invasive disease.
Secondary Outcomes
- Pathological complete response rate(From date of enrollment up to 24 weeks)
- overall survival(From date of enrollment through study completion, up to 10 years.)